(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced results of new clinical research of its Immuno-Oncology agents - Opdivo and Yervoy - will be presented at the Society for Melanoma Research (SMR) 2015 International Congress in San Francisco, CA from November 18 - 21. Studies to be presented at SMR illustrate Bristol-Myers Squibb's scientific commitment, through its Immuno-Oncology research, to developing treatment options for patients with advanced melanoma. Michael Giordano, M.D., senior vice president, head of Development, Oncology, Bristol-Myers Squibb commented, 'The new research to be presented at SMR,...
↧